

Living Cell Technologies Awarded Most Improved Small-Medium Business in Kenexa Best Workplaces Awards 2013

1 November 2013 – Auckland, New Zealand – Living Cell Technologies (ASX: LCT) has been awarded the Kenexa Best Workplaces ‘Most Improved Award’ 2013 in the small-medium business category. The Kenexa Best Workplaces is New Zealand’s largest annual workplace climate-employee engagement survey.

Andrea Grant, Living Cell Technologies managing director, is delighted with the company’s award.

“Team building is an art and at LCT we make it our business to attract, nurture and help our people excel in their chosen profession. And I’m delighted that the ‘Most Improved Award’ recognises our continuing efforts.

“It’s a very special feeling to know that our team feel positively towards the company. LCT wouldn’t be a leader in cell therapies to treat disease without putting our people first. This recognition is a validation of our work and inspires us to constantly keep improving the quality of our workplace relations,” said Dr Grant.

The Kenexa Best Workplaces survey is run in association with *The New Zealand Herald* and is supported by Kiwibank, the Employers and Manufacturers Association and the Ministry of Business, Innovation & Employment. Over 39,000 employees from 240 companies took part in the survey – identifying areas that make their workplace great as well as which areas they can improve to increase levels of engagement.

Numerous studies have shown a direct correlation between employee engagement and business success. A Gallup study found that highly engaged organisations have double the rate of success of less engaged organisations.

LCT was chosen for the ‘Most Improved Award’ in the small-medium business category. The company showed the most improvement across several behaviour-related questions in the survey.

– Ends –

For further information: www.lctglobal.com

At the company:

Dr Andrea Grant
 Managing Director
 Tel: +64 9 270 7941
 Mobile: +64 21 078 5421
agrant@lctglobal.com

Media - NZ:

Rachael Joel
 Botica Butler Raudon Partners
 Tel: +64 9 303 3862
 Mobile: +64 21 403 504
rachaelj@botica.co.nz

About Living Cell Technologies

Living Cell Technologies (LCT) is an Australasian biotechnology company and world leader in developing cell therapies to treat diseases with high unmet clinical need. To date, the company has taken two therapeutic candidates into clinical development: DIABECCELL® for the treatment of Type 1 diabetes and NTCELL®, which is in Phase I clinical trials in New Zealand for the treatment of Parkinson’s disease.

Through an innovative joint venture with international pharmaceutical company Otsuka Pharmaceutical Factory (OPF), LCT has secured funding, based on the achievement of clinical milestones, for the clinical development of DIABECCELL and the Phase I clinical trials of NTCELL in Parkinson's disease. LCT retains a 50% share of future profits from DIABECCELL and NTCELL and a perpetual, exclusive licence to continue to develop products using intellectual property held outside the DOL partnership.

LCT's unique, proprietary technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system, which often have negative side-effects.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential", "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.